Edition:
India

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

22.08USD
17 Sep 2019
Change (% chg)

$-0.14 (-0.65%)
Prev Close
$22.22
Open
$22.10
Day's High
$22.10
Day's Low
$22.08
Volume
753
Avg. Vol
71,786
52-wk High
$37.73
52-wk Low
$18.71

Latest Key Developments (Source: Significant Developments)

Akcea Reports Q2 2019 Results
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR SECOND QUARTER 2019.AKCEA THERAPEUTICS INC - QTRLY TOTAL REVENUE $27 MILLION.AKCEA THERAPEUTICS INC - AS OF JUNE 30, 2019, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $296 MILLION COMPARED TO $253 MILLION AT DECEMBER 31, 2018.  Full Article

Akcea And Ionis Announce Approval Of Waylivra In The European Union
Tuesday, 7 May 2019 

May 7 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS ANNOUNCE APPROVAL OF WAYLIVRA® (VOLANESORSEN) IN THE EUROPEAN UNION.AKCEA THERAPEUTICS - APPROVAL OF WAYLIVRA IN EU AS ADJUNCT TO DIET IN ADULT PATIENTS WITH GENETICALLY CONFIRMED FCS AND AT HIGH RISK FOR PANCREATITIS.  Full Article

Akcea Reports Financial Results For Fourth Quarter
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND YEAR END 2018.Q4 LOSS PER SHARE $0.79.Q4 EARNINGS PER SHARE ESTIMATE $-0.73 -- REFINITIV IBES DATA.TOTAL REVENUE FOR Q4 $10 MILLION.  Full Article

Akcea And Ionis Receive FDA Approval Of Tegsedi (Inotersen) For The Treatment Of The Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Saturday, 6 Oct 2018 

Oct 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS RECEIVE FDA APPROVAL OF TEGSEDI (INOTERSEN) FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS.AKCEA THERAPEUTICS INC - TEGSEDI IS NOW APPROVED IN U.S., EUROPEAN UNION AND CANADA.  Full Article

Akcea Therapeutics Inc QTRLY Net Loss Per Share Of Common Stock Was $0.72
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Akcea Therapeutics Inc ::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR SECOND QUARTER 2018.AKCEA THERAPEUTICS INC QTRLY RESEARCH AND DEVELOPMENT REVENUE $18.3 MILLION VERSUS $5.7 MILLION.AKCEA THERAPEUTICS INC QTRLY NET LOSS PER SHARE OF COMMON STOCK [OWNED BY IONIS] WAS $0.72.AKCEA THERAPEUTICS INC QTRLY NET LOSS PER SHARE OF COMMON STOCK [OWNED BY OTHERS] WAS $0.85.  Full Article

Akcea Therapeutics, PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Akcea Therapeutics Inc ::AKCEA THERAPEUTICS AND PTC THERAPEUTICS COLLABORATE TO COMMERCIALIZE TWO RARE DISEASE DRUGS IN LATIN AMERICA.AKCEA THERAPEUTICS - PTC TO COMMERCIALIZE 2 OF CO'S RARE DISEASE DRUGS IN LATAM: TEGSEDI (INOTERSEN) AND WAYLIVRA (VOLANESORSEN).AKCEA THERAPEUTICS INC - PTC WILL GAIN EXCLUSIVE RIGHTS TO TEGSEDI AND WAYLIVRA IN LATIN AMERICA AND CERTAIN CARIBBEAN COUNTRIES.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA AN UPFRONT LICENSING FEE OF $18 MILLION, $12 MILLION.AKCEA THERAPEUTICS INC - UPFRONT LICENSING FEE IS DUE ON SIGNING AND $6 MILLION WHICH WILL BE PAID ON EARLIER OF FDA OR EMA APPROVAL OF WAYLIVRA.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA REGULATORY MILESTONES IN PTC TERRITORY UP TO A TOTAL OF $8 MILLION.AKCEA THERAPEUTICS INC - CO IS ALSO ELIGIBLE TO RECEIVE ROYALTIES FROM PTC IN MID-TWENTY PERCENT RANGE ON NET SALES OF EACH DRUG IN PTC TERRITORY.AKCEA THERAPEUTICS INC - COLLABORATION WILL BE GOVERNED BY A JOINT STEERING COMMITTEE WITH REPRESENTATION FROM BOTH PARTIES.  Full Article

Akcea And Ionis Announce Approval Of Tegsedi In The EU
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Akcea Therapeutics Inc ::AKCEA AND IONIS ANNOUNCE APPROVAL OF TEGSEDI™ (INOTERSEN) IN THE EUROPEAN UNION.AKCEA THERAPEUTICS INC - TEGSEDI'S U.S. PRESCRIPTION DRUG USER FEE ACT, OR PDUFA, DATE IS OCTOBER 6, 2018.  Full Article

Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE.AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article